Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential

Treatment of chronic hepatitis C (HCV) is currently undergoing a significant change. Traditional interferon-based therapy has been limited by both efficacy and tolerability, and many direct acting antiviral (DAA) drugs are emerging. Sofosbuvir (GS-7977) is a HCV NS5B nucleotide polymerase inhibitor that has now been evaluated extensively in phase II and III interferon-free clinical trials. The focus of this review is on the clinical potential of sofosbuvir in the treatment of HCV. Sofosbuvir has a pan-genotypic effect on HCV, although viral genotype-specific differences in sustained virological response (SVR) have emerged in phase III clinical trials. Sofosbuvir has been studied both as dual therapy with ribavirin and also as triple therapy with either NS5A inhibitors or a protease inhibitor. High rates of SVR have been reported with these interferon-free combinations, particularly with genotypes 1 and 2, and the safety profile has been very favourable in both cirrhotic and noncirrhotic patients, without issues of viral resistance. Interferon-free, once-daily treatment of HCV is now becoming a reality.

[1]  E. Lawitz,et al.  1130 THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS AND ANTIVIRAL ACTIVITY OF PSI-7977 IN HEPATITIS C INFECTED SUBJECTS TREATED FOR SEVEN DAYS , 2012 .

[2]  John McNally,et al.  Sofosbuvir for previously untreated chronic hepatitis C infection. , 2013, The New England journal of medicine.

[3]  Todd M. Allen,et al.  Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment‐naïve patients , 2008, Hepatology.

[4]  Geoffrey Dusheiko,et al.  Telaprevir for previously untreated chronic hepatitis C virus infection. , 2011, The New England journal of medicine.

[5]  M. Manns,et al.  Boceprevir for untreated chronic HCV genotype 1 infection. , 2011, The New England journal of medicine.

[6]  C. Stedman,et al.  Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. , 2013, The New England journal of medicine.

[7]  R. Fontana,et al.  Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  M. Otto,et al.  Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. , 2010, Journal of medicinal chemistry.

[9]  K. Reddy,et al.  Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection , 2013, Expert opinion on investigational drugs.

[10]  E. Schiff,et al.  Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. , 2013, The New England journal of medicine.

[11]  C. Stedman,et al.  Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. , 2014, Gastroenterology.

[12]  Sprint Investigators,et al.  Boceprevir for Untreated Chronic HCV Genotype 1 Infection , 2011 .

[13]  C. Stedman,et al.  14 ALL-ORAL SOFOSBUVIR-BASED 12-WEEK REGIMENS FOR THE TREATMENT OF CHRONIC HCV INFECTION: THE ELECTRON STUDY , 2013 .

[14]  K. Kowdley,et al.  Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial. , 2013, Journal of hepatology.

[15]  K. Reddy,et al.  Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. , 2013, The Lancet. Infectious diseases.

[16]  J. Murray,et al.  Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. , 2013, Gastroenterology.

[17]  T. Marbury,et al.  1101 THE EFFECT OF RENAL IMPAIRMENT AND END STAGE RENAL DISEASE ON THE SINGLE-DOSE PHARMACOKINETICS OF PSI-7977 , 2012 .

[18]  D. Samuel,et al.  Autoimmune acute liver failure , 2011, Hepatology.

[19]  F. Carrat,et al.  60 SVR12 RATES AND SAFETY OF TRIPLE THERAPY INCLUDING TELAPREVIR OR BOCEPREVIR IN 221 CIRRHOTIC NON RESPONDERS TREATED IN THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC) , 2013 .

[20]  M. Otto,et al.  Genotype and Subtype Profiling of PSI-7977 as a Nucleotide Inhibitor of Hepatitis C Virus , 2012, Antimicrobial Agents and Chemotherapy.

[21]  M. Otto,et al.  Mechanism of Activation of PSI-7851 and Its Diastereoisomer PSI-7977 , 2010, The Journal of Biological Chemistry.

[22]  T. Hassanein,et al.  848 HIGH CONCORDANCE OF SVR4, SVR12, AND SVR24 IN PATIENTS WITH HCV INFECTION WHO HAVE RECEIVED TREATMENT WITH SOFOSBUVIR , 2013 .

[23]  A. Lok,et al.  1417 SUSTAINED VIROLOGIC RESPONSE WITH DACLATASVIR PLUS SOFOSBUVIR ± RIBAVIRIN (RBV) IN CHRONIC HCV GENOTYPE (GT) 1-INFECTED PATIENTS WHO PREVIOUSLY FAILED TELAPREVIR (TVR) OR BOCEPREVIR (BOC) , 2013 .

[24]  T. Hassanein,et al.  Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial , 2013, The Lancet.